| Synonyms: | |
| Status: | Approved (1987) |
| Entry Type: | Small molecule |
| Molecule Category: | Parent |
| ATC: | C09AA03 |
| UNII: | 7Q3P4BS2FD |
| InChI Key | RLAWWYSOJDYHDC-BZSNNMDCSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C21H35N3O7 |
| Molecular Weight | 441.53 |
| AlogP | 1.24 |
| Hydrogen Bond Acceptor | 5.0 |
| Hydrogen Bond Donor | 4.0 |
| Number of Rotational Bond | 12.0 |
| Polar Surface Area | 132.96 |
| Molecular species | ZWITTERION |
| Aromatic Rings | 1.0 |
| Heavy Atoms | 29.0 |
| Action | Mechanism of Action | Reference |
|---|---|---|
| INHIBITOR | Angiotensin-converting enzyme inhibitor | FDA |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Enzyme
Protease
Metallo protease
Metallo protease MAE clan
Metallo protease M2 family
|
- | 0-8 | - | 51-132 | 7 | |
|
Transporter
Electrochemical transporter
SLC superfamily of solute carriers
SLC21/SLCO family of organic anion transporting polypeptides
|
- | - | - | - | 5-83 |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Heart Failure | 4 | D006333 | FDA |
| Myocardial Infarction | 4 | D009203 | FDA |
| Hypertrophy, Left Ventricular | 3 | D017379 | ClinicalTrials |
| Hyperoxaluria, Primary | 3 | D006960 | ClinicalTrials |
| Cardiovascular Diseases | 3 | D002318 | ClinicalTrials |
| Diabetes Mellitus | 3 | D003920 | ClinicalTrials |
| Diabetic Nephropathies | 3 | D003928 | ClinicalTrials |
| Hypertension | 3 | D006973 | ClinicalTrials |
| Diabetes Mellitus, Type 2 | 3 | D003924 | ClinicalTrials |
| Heart Failure | 3 | D006333 | ClinicalTrials |
| Myocardial Infarction | 3 | D009203 | ClinicalTrials |
| Atherosclerosis | 3 | D050197 | ClinicalTrials |
| Polycystic Kidney Diseases | 3 | D007690 | ClinicalTrials |
| Myocardial Ischemia | 3 | D017202 | ClinicalTrials |
| Hypercholesterolemia | 3 | D006937 | ClinicalTrials |
| Heart Failure | 3 | D006333 | ClinicalTrials |
| Coronary Disease | 3 | D003327 | ClinicalTrials |
| Non-alcoholic Fatty Liver Disease | 2 | D065626 | ClinicalTrials |
| Glomerulosclerosis, Focal Segmental | 2 | D005923 | ClinicalTrials |
| Essential Hypertension | 2 | D000075222 | ClinicalTrials |
| Lymphoma | 2 | D008223 | ClinicalTrials |
| Carcinoma, Hepatocellular | 2 | D006528 | ClinicalTrials |
| Lupus Erythematosus, Systemic | 2 | D008180 | ClinicalTrials |
| Glomerulonephritis | 2 | D005921 | ClinicalTrials |
| Breast Neoplasms | 2 | D001943 | ClinicalTrials |
| Azoospermia | 2 | D053713 | ClinicalTrials |
| Stroke | 1 | D020521 | ClinicalTrials |
| Gastroparesis | 1 | D018589 | ClinicalTrials |
| Lecithin Cholesterol Acyltransferase Deficiency | 1 | D007863 | ClinicalTrials |
| Vascular Diseases | 1 | D014652 | ClinicalTrials |
| Resources | Reference |
|---|---|
| ChEBI | 43755 |
| ChEMBL | CHEMBL1237 |
| DrugBank | DB00722 |
| DrugCentral | 1587 |
| EPA CompTox | DTXSID6040537 |
| FDA SRS | 7Q3P4BS2FD |
| Human Metabolome Database | HMDB0001938 |
| Guide to Pharmacology | 6360 |
| PDB | LPR |
| PharmGKB | PA450242 |
| SureChEMBL | SCHEMBL15680 |
| ZINC | ZINC000003812863 |
| ChEBI | 6503 |
| ChEMBL | CHEMBL419213 |
| EPA CompTox | DTXSID2045600 |
| FDA SRS | E7199S1YWR |
| SureChEMBL | SCHEMBL542591 |